Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter?

Journal of Stroke and Cerebrovascular Diseases

Volumn 12, Issue 1, 2003, Pages 29-36

  Swartz, Richard H ^a,b   Sahlas, Demetrios J ^b   Black, Sandra E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Acetylcholine; Alzheimer's disease; Executive function; Hyperintensities; Vascular dementia; White matter

Indexed keywords

ACETYLCHOLINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIGNAL HYPERINTENSITY; SIGNAL PROCESSING; STATISTICAL ANALYSIS; TEMPORAL LOBE; WHITE MATTER;

EID: 0037219650     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2003.5     Document Type: Article

References (40)

1. Hulette C, Nochlin D, McKeel D, et al. Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997;48:668-672.
2. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-817.
3. Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-25.
4. Perry EK. The cholinergic system in old age and Alzheimer's disease. Age Ageing 1980;9:1-8.
5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56: 1154-1166.
6. Erkinjuntii T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 2002;359:1283-1290.
7. Perdomo CA, Pratt RD. A comparison of the effects of donepezil in patients with probable and possible vascular dementia: A combined analysis of two 24-week, randomized, double-blind, placebo-controlled trials (abstract). Neurology 2002;58:A382 (suppl 3).
8. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275: 216-240.
9. Selden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249-2257.
10. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995;9:43-49.
11. Johnson DA, Zambon NJ, Gibbs RB. Selective lesion of cholinergic neurons in the medial septum by 192 IgG-saporin impairs learning in a delayed matching to position T-maze paradigm. Brain Res 2002;943:132-141.
12. Muir JL, Page KJ, Sirinathsinghji DJ, et al. Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav Brain Res 1993; 57:123-131.
13. Voytko ML, Olton DS, Richardson RT, et al. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 1994;14:167-186.
14. Pang K, Williams MJ, Egeth H, et al. Nucleus basalis magnocellularis and attention: effects of muscimol infusions. Behav Neurosci 1993;107:1031-1038.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC, American Psychiatric Association. 1994;4.
16. McKhann G, Drachman DA, Folstein MF, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Workgroup under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
18. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-1796.
19. Mattis S. Mental Status Examination for Organic Mental Syndrome in the Elderly Patient, in: Bellak L, Karasu TB, eds. Geriatric Psychiatry. New York: Grune and Stratton, 1976.
20. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: Adult Version. San Antonio, Texas: The Psychological Corporation, 1987.
21. Wechsler D. Wechsler Memory Scale - Revised. New York: The Psychological Corporation, 1987.
22. Lezack MD. Neuropsychological assessment. New York: Oxford University Press, 1983.
23. Heaton RK. Wisconsin Card Sorting Test manual. Odessa, Florida: Psychological Assessment Resources, 1981.
24. Benton AL, Hamsher K, Varney NR, et al. Contributions to Neuropsychological Assessment. New York: Oxford University Press, 1983.
25. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. Boston: Lea and Febiger, 1978.
26. Gao FQ, Black SE, Leibovitch FS, et al. A reliable MR measurement of medial temporal lobe width from the Sunnybrook Dementia Study. Neurobiol Aging 2003;24:49-56.
27. Fleiss JL. Reliability of measurement. The Design and Analysis of Clinical Experiments. New York: John Wiley and Sons, 1986;1-32.
28. Wenk GL. The nucleus basalis magnocellularis cholinergic system: one hundred years of progress. Neurobiol Learn Mem 1997;67:85-95.
29. Hirono N, Kitagaki H, Kazui H, et al. Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke 2000;31:2182-2188.
30. Lee J-H, Olichney JM, Hansen LA, et al. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol 2000;57:1474-1479.
31. Esiri MM, Nagy Z, Smith MZ, et al. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999;354:919-920.
32. Tsiskaridze A, Shakarishvili R, Janelidze M, et al. Cognitive correlates of leukoaraiosis in the early stages of Alzheimer's disease. Funct Neurol 1998;13: 17-25.
33. DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-2084.
34. Amar K, Bucks RS, Lewis T, et al. The effect of white matter low attenuation on cognitive performance in dementia of the Alzheimer type. Age Ageing 1996;25:443-448.
35. Gold G, Giannakopoulos P, Montes-Paixao JC, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997; 49:690-694.
36. Roses AD, Saunders AM. Clinical overdiagnosis of vascular dementia versus necropsy confirmed series. J Neurol Neurosurg Psychiatry 1997;62:677-678.
37. van Gijn J. Leukoaraiosis and vascular dementia. Neurology 1998;51:S3-S8.
38. Pantoni L, Leys D, Fazekas F, et al. Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 1999;13:S49.-S54.
39. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30.
40. Lee SC, Park SJ, Ki HK, et al. Prevalence and risk factors of silent cerebral infarction in apparently normal adults. Hypertension 2000;36:73-77.